The Effect of Heel Skin Mechanoreceptors on Plantar Flexor Contraction Force

February 26, 2026 updated by: Berk Kutsal, Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Previous studies have shown that stimulation of heel skin mechanoreceptors facilitates the soleus H-reflex, whereas stimulation of metatarsal region mechanoreceptors inhibits the soleus H-reflex. From this perspective, plantar cutaneous receptors may play an important role in the regulation of activities such as walking and running, as well as in the control of spasticity in patients with upper motor neuron lesions. Investigating the effect of heel skin mechanoreceptors on plantar flexor muscle contraction force may provide valuable insight into the potential influence of these mechanoreceptors on locomotor activities and muscle tone, and may offer a foundation for future studies directly addressing these topics.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The aim of this study is to investigate the effect of heel skin mechanoreceptors on plantar flexor contraction force. The plantar flexor muscle strength of the participants was evaluated using a force sensor connected to a computer. For the isometric muscle strength measurement, the subjects were asked to perform maximal plantar flexion for 10 seconds. A 5-pulse stimulation package at 15% contraction level was delivered 10 times with a 4-6 second interval. The measurements were repeated 10 times with a 30-second interval. During the plantar flexion muscle strength measurement, the heel skin mechanoreceptors were stimulated at sensory threshold by a square wave electrical current with a pulse duration of 1 microsecond.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
29

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Istanbul
      • Istanbul, Istanbul, Turkey (Türkiye), 34180
        • Istanbul Physical Medicine and Rehabilitation Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Being healthy
  • Being between 20 and 40 years of age
  • Being female or male
  • Volunteering to participate

Exclusion Criteria:

  • Having a history of orthopedic conditions-particularly in the lower extremity-or residual neuromusculoskeletal problems due to previously experienced illnesses

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Prone position
Plantar flexor muscle strength is assessed in the supine position. For the measurement of isometric muscle strength, participants lay prone on an examination table and were instructed to perform maximal plantar flexion for 10 seconds. To achieve a submaximal contraction corresponding to 15% of their maximal voluntary contraction, participants were asked to follow a 15% threshold reference line displayed on the force channel monitor.
Other: Assesment of Plantar Flexion Muscle Strength During Heel Skin Mechanoreceptor Stimulation

For the measurement of isometric muscle strength, participants lying prone on an examination table were instructed to perform maximal plantar flexion for 10 seconds. To achieve a submaximal contraction corresponding to 15% of their maximal contraction force, they were asked to follow the 15% threshold reference line displayed on the force channel on the screen.

During the measurement of plantar flexion muscle strength, the cutaneous mechanoreceptors of the heel were stimulated with a square-wave electrical current with a pulse duration of 1 microsecond, at an intensity three times the sensory threshold. Electrical stimulation was delivered via a constant-current stimulator (Digitimer DS7A, Hertfordshire, United Kingdom). At the 15% contraction level, a train of five stimuli was delivered 10 times at intervals of 4-6 seconds. Measurements were repeated 10 times with 30-second intervals between each set.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Voluntary Contraction Force
Time Frame: Day 1 (During a single experimental session)
While the participants were lying prone on the examination table, plantar flexion muscle strength was assessed using a computer-connected force sensor (SPIKE 2.7). For detailed analysis of the participant data using the SPIKE 2.7 force sensor software, an IIR digital filtering process was first applied to the force channel. During this procedure, a low-pass filter was selected. The filter settings were configured with a cutoff value of 100 and an order of 2. As a result of this filtering process, the newly generated filtered memory channel was labeled "ForceLP." Subsequently, the waveform average of the ForceLP channel was calculated with the following settings: width 4 s, offset 2 s, and trigger set to 6 stimuli (event+). From these averaged traces peak contraction force was determined.
Day 1 (During a single experimental session)
Reflex Contraction Force
Time Frame: Day 1 (During a single experimental session)
While the participants were lying prone on the examination table, plantar flexion muscle strength was assessed using a computer-connected force sensor (SPIKE 2.7). For detailed analysis of the participant data using the SPIKE 2.7 force sensor software, an IIR digital filtering process was first applied to the force channel. During this procedure, a low-pass filter was selected. The filter settings were configured with a cutoff value of 100 and an order of 2. As a result of this filtering process, the newly generated filtered memory channel was labeled "ForceLP." Subsequently, the waveform average of the ForceLP channel was calculated with the following settings: width 4 s, offset 2 s, and trigger set to 6 stimuli (event+). From these averaged traces reflex contraction force was determined.
Day 1 (During a single experimental session)
Reflex Contraction Latency
Time Frame: Day 1 (During a single experimental session)
While the participants were lying prone on the examination table, plantar flexion muscle strength was assessed using a computer-connected force sensor (SPIKE 2.7). For detailed analysis of the participant data using the SPIKE 2.7 force sensor software, an IIR digital filtering process was first applied to the force channel. During this procedure, a low-pass filter was selected. The filter settings were configured with a cutoff value of 100 and an order of 2. As a result of this filtering process, the newly generated filtered memory channel was labeled "ForceLP." Subsequently, the waveform average of the ForceLP channel was calculated with the following settings: width 4 s, offset 2 s, and trigger set to 6 stimuli (event+). From these averaged traces reflex contraction latency was determined.
Day 1 (During a single experimental session)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Physical Medicine Rehabilitation Training and Research Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 23, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 20, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 23, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 27, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 27, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 26, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2025-58

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heel Skin Mechanoreceptors

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings